Show simple item record

dc.contributor.authorJudson, Ian R
dc.contributor.authorRadford, John A
dc.contributor.authorHarris, Maggie A
dc.contributor.authorBlay, Jean-Yves
dc.contributor.authorVan Hoesel, Q
dc.contributor.authorLe Cesne, A
dc.contributor.authorVan Oosterom, A
dc.contributor.authorClemons, Mark
dc.contributor.authorKamby, C
dc.contributor.authorHermans, C
dc.contributor.authorWhittaker, J
dc.contributor.authorDonato di Paola, E
dc.contributor.authorVerweij, Jaap
dc.contributor.authorNielsen, S
dc.date.accessioned2009-10-02T15:26:51Z
dc.date.available2009-10-02T15:26:51Z
dc.date.issued2001-05
dc.identifier.citationRandomised phase II trial of pegylated liposomal doxorubicin (DOXILR/CAELYXR) versus doxorubicin in the treatment of advanced or metastatic sift tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. 2001, 37(7) : 870-877 Eur J Canceren
dc.identifier.issn09598049
dc.identifier.doi10.1016/S0959-8049(01)00050-8
dc.identifier.urihttp://hdl.handle.net/10541/83378
dc.language.isoenen
dc.subjectSoft Tissue Sarcomaen
dc.subjectDoxorubicinen
dc.subjectLiposomal Doxorubicinen
dc.subjectRandomized Phase II Trialen
dc.titleRandomised phase II trial of pegylated liposomal doxorubicin (DOXILR/CAELYXR) versus doxorubicin in the treatment of advanced or metastatic sift tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Groupen
dc.typeArticleen
dc.contributor.departmentRoyal Marsden Hospital, London, UKen
dc.identifier.journalEuropean Journal of Canceren


Files in this item

This item appears in the following Collection(s)

Show simple item record